ozdogan_md· @ozdogan_md · X·· 3 days agoScore60
Body · original
DASL-HiCaP tests darolutamide + ADT + RT in very-high-risk localised prostate cancer, with MFS as the primary endpoint. The result magnitude is still pending. Key question: will the benefit justify 96 weeks of added therapy and toxicity? @niazi_Dr7 @ChrisSweens1 @myESMO #ESMO26 #ProstateCancer
Heat 10 · 5 likes · 0 replies · 5 reposts
Conference abstracts
NCT04136353NCT04136353matched by - **标题 / Title：** Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
- **标题 / Title：** Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the ProstateRead the abstract →Source: ozdogan_md · x.com